PE20171060A1 - Receptores quimericos de antigeno anti-cldn y metodos de uso - Google Patents
Receptores quimericos de antigeno anti-cldn y metodos de usoInfo
- Publication number
- PE20171060A1 PE20171060A1 PE2017000813A PE2017000813A PE20171060A1 PE 20171060 A1 PE20171060 A1 PE 20171060A1 PE 2017000813 A PE2017000813 A PE 2017000813A PE 2017000813 A PE2017000813 A PE 2017000813A PE 20171060 A1 PE20171060 A1 PE 20171060A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cldn
- chemerical
- receptors
- methods
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 102000002029 Claudin Human genes 0.000 abstract 1
- 108050009302 Claudin Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se refiere a un receptor quimerico de antigeno que comprende un dominio de union anti claudina (anti-CLDN), donde el dominio de union comprende un dominio scFv de union anti-CLDN de una region variable de cadena liviana (VL) de SEQ ID NO: 21 y una region variable de cadena pesada (VH) de SEQ ID NO: 23; o una VL de SEQ ID:25 y una VH de SEQ ID NO:27; o una VL de SEQ ID:29 y una VH de SEQ ID NO:31; o una VL de SEQ ID:33 y una VH de SEQ ID NO:35; o una VL de SEQ ID:37 y una VH de SEQ ID NO:39; o una VL de SEQ ID:41 y una VH de SEQ ID NO:43; o una VL de SEQ ID:45 y una VH de SEQ ID NO:47; o una VL de SEQ ID:49 y una VH de SEQ ID NO:51; o una VL de SEQ ID:53 y una VH de SEQ ID NO:55; o una VL de SEQ ID:57 y una VH de SEQ ID NO:59. Tambien se refiere a una composicion farmaceutica y un kit. Dicho receptor tiene utilidad en el tratamiento de cancer de pulmon
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/064165 WO2015069794A2 (en) | 2013-11-06 | 2014-11-05 | Novel anti-claudin antibodies and methods of use |
| US201562157928P | 2015-05-06 | 2015-05-06 | |
| US201562247108P | 2015-10-27 | 2015-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171060A1 true PE20171060A1 (es) | 2017-07-21 |
Family
ID=55909771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000813A PE20171060A1 (es) | 2014-11-05 | 2015-11-04 | Receptores quimericos de antigeno anti-cldn y metodos de uso |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20170334991A1 (es) |
| EP (1) | EP3215523A4 (es) |
| JP (1) | JP2017535283A (es) |
| KR (1) | KR20170085531A (es) |
| CN (1) | CN107207580A (es) |
| AU (1) | AU2015343079A1 (es) |
| BR (1) | BR112017009517A2 (es) |
| CA (1) | CA2966618A1 (es) |
| CL (1) | CL2017001118A1 (es) |
| CO (1) | CO2017005538A2 (es) |
| CR (1) | CR20170235A (es) |
| DO (1) | DOP2017000110A (es) |
| EA (1) | EA201790967A1 (es) |
| EC (1) | ECSP17031725A (es) |
| IL (1) | IL252090A0 (es) |
| MA (1) | MA40921A (es) |
| MX (1) | MX2017005797A (es) |
| PE (1) | PE20171060A1 (es) |
| PH (1) | PH12017500825A1 (es) |
| SG (1) | SG11201703669YA (es) |
| TW (1) | TW201625677A (es) |
| WO (1) | WO2016073649A1 (es) |
| ZA (1) | ZA201703471B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120058178A1 (en) | 2009-03-30 | 2012-03-08 | Eisai R&D Management Co., Ltd. | Liposome Composition |
| US10053511B2 (en) * | 2013-11-06 | 2018-08-21 | Abbvie Stemcentrx Llc | Anti-claudin antibodies and methods of use |
| JP7015237B2 (ja) | 2016-04-28 | 2022-02-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| AU2017342462A1 (en) * | 2016-10-14 | 2019-05-02 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and eribulin for treating urothelial cancer |
| TWI820044B (zh) | 2017-09-29 | 2023-11-01 | 日商第一三共股份有限公司 | 抗體－吡咯并苯二氮呯衍生物複合體 |
| US12454694B2 (en) | 2018-09-07 | 2025-10-28 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| US12529041B2 (en) | 2018-09-07 | 2026-01-20 | Beam Therapeutics Inc. | Compositions and methods for delivering a nucleobase editing system |
| JP2022517301A (ja) * | 2018-12-07 | 2022-03-08 | カファ セラピューティクス リミテッド | 腫瘍併用免疫療法 |
| KR20210126008A (ko) * | 2019-01-07 | 2021-10-19 | 카르스젠 테라퓨틱스 컴퍼니, 리미티드 | 세포 면역 치료의 조합 |
| DK3920939T3 (da) * | 2019-02-08 | 2025-01-13 | Biontech Cell & Gene Therapies Gmbh | Kimæriske antigenreceptormodificerede celler til behandling af cldn6-udtrykkende cancere |
| WO2020205759A1 (en) * | 2019-03-29 | 2020-10-08 | Pact Pharma, Inc. | Personalized neoantigen-specific adoptive cell therapies |
| CN113825771B (zh) | 2019-05-16 | 2024-02-09 | 齐鲁制药有限公司 | 针对密蛋白18a2的抗体及其应用 |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2021129927A1 (en) * | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| CN113637082A (zh) * | 2020-04-27 | 2021-11-12 | 启愈生物技术(上海)有限公司 | 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用 |
| US20210347847A1 (en) * | 2020-05-11 | 2021-11-11 | The Broad Institute, Inc. | Therapeutic targeting of malignant cells using tumor markers |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN116940377A (zh) * | 2021-03-05 | 2023-10-24 | 上海吉倍生物技术有限公司 | 抗cldn6抗体及其用途 |
| CN114478802B (zh) * | 2022-01-28 | 2023-05-26 | 郑州大学 | 一种嵌合抗原受体及其应用 |
| CN116063507A (zh) * | 2022-05-11 | 2023-05-05 | 迈威(上海)生物科技股份有限公司 | 抗人gas6抗体或其抗原结合片段及其应用 |
| CN120225555A (zh) * | 2022-10-25 | 2025-06-27 | 恺兴生命科技(上海)有限公司 | 抗体及其应用 |
| CN117169518B (zh) * | 2023-11-03 | 2024-01-19 | 赛德特(北京)生物工程有限公司 | T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒 |
| WO2025209525A1 (zh) * | 2024-04-03 | 2025-10-09 | 江苏恒瑞医药股份有限公司 | 抗cldn6抗体、其抗体-药物偶联物及其医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101074261A (zh) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
| WO2008105560A1 (ja) * | 2007-02-27 | 2008-09-04 | Forerunner Pharma Research Co., Ltd. | 抗grp78抗体を有効成分として含む医薬組成物 |
| US9274119B2 (en) * | 2008-01-11 | 2016-03-01 | The University Of Tokyo | Anti-CLDN6 antibody |
| DK2499161T3 (da) * | 2009-11-11 | 2017-11-27 | Ganymed Pharmaceuticals Gmbh | Antistoffer, der er specifikke for claudin 6 (cldn6) |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US10053511B2 (en) * | 2013-11-06 | 2018-08-21 | Abbvie Stemcentrx Llc | Anti-claudin antibodies and methods of use |
| PT3708579T (pt) * | 2014-04-01 | 2024-07-17 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Imunorrecetores e epitopos de células t específicos para claudina-6 |
| WO2016180467A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
| CR20180348A (es) * | 2015-12-04 | 2018-08-23 | Abbvie Stemcentrx Llc | Nuevos anticuerpos anti-claudina y sus métodos de uso |
-
2015
- 2015-11-03 MA MA040921A patent/MA40921A/fr unknown
- 2015-11-04 MX MX2017005797A patent/MX2017005797A/es unknown
- 2015-11-04 SG SG11201703669YA patent/SG11201703669YA/en unknown
- 2015-11-04 CR CR20170235A patent/CR20170235A/es unknown
- 2015-11-04 EA EA201790967A patent/EA201790967A1/ru unknown
- 2015-11-04 CA CA2966618A patent/CA2966618A1/en not_active Abandoned
- 2015-11-04 KR KR1020177015413A patent/KR20170085531A/ko not_active Withdrawn
- 2015-11-04 PE PE2017000813A patent/PE20171060A1/es not_active Application Discontinuation
- 2015-11-04 AU AU2015343079A patent/AU2015343079A1/en not_active Abandoned
- 2015-11-04 WO PCT/US2015/059106 patent/WO2016073649A1/en not_active Ceased
- 2015-11-04 CN CN201580072018.5A patent/CN107207580A/zh active Pending
- 2015-11-04 BR BR112017009517A patent/BR112017009517A2/pt not_active Application Discontinuation
- 2015-11-04 EP EP15857690.0A patent/EP3215523A4/en not_active Withdrawn
- 2015-11-04 US US15/524,675 patent/US20170334991A1/en not_active Abandoned
- 2015-11-04 JP JP2017543306A patent/JP2017535283A/ja active Pending
- 2015-11-05 TW TW104136552A patent/TW201625677A/zh unknown
-
2017
- 2017-05-02 DO DO2017000110A patent/DOP2017000110A/es unknown
- 2017-05-03 IL IL252090A patent/IL252090A0/en unknown
- 2017-05-04 PH PH12017500825A patent/PH12017500825A1/en unknown
- 2017-05-05 CL CL2017001118A patent/CL2017001118A1/es unknown
- 2017-05-19 ZA ZA2017/03471A patent/ZA201703471B/en unknown
- 2017-05-25 EC ECIEPI201731725A patent/ECSP17031725A/es unknown
- 2017-06-02 CO CONC2017/0005538A patent/CO2017005538A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017001118A1 (es) | 2018-01-05 |
| DOP2017000110A (es) | 2017-05-31 |
| EP3215523A1 (en) | 2017-09-13 |
| TW201625677A (zh) | 2016-07-16 |
| AU2015343079A1 (en) | 2017-05-25 |
| CN107207580A (zh) | 2017-09-26 |
| CR20170235A (es) | 2017-07-21 |
| MX2017005797A (es) | 2017-10-23 |
| JP2017535283A (ja) | 2017-11-30 |
| SG11201703669YA (en) | 2017-06-29 |
| EP3215523A4 (en) | 2018-06-20 |
| ZA201703471B (en) | 2019-06-26 |
| CA2966618A1 (en) | 2016-05-12 |
| US20170334991A1 (en) | 2017-11-23 |
| KR20170085531A (ko) | 2017-07-24 |
| BR112017009517A2 (pt) | 2017-12-19 |
| MA40921A (fr) | 2017-09-12 |
| ECSP17031725A (es) | 2017-06-30 |
| IL252090A0 (en) | 2017-07-31 |
| EA201790967A1 (ru) | 2017-10-31 |
| WO2016073649A1 (en) | 2016-05-12 |
| PH12017500825A1 (en) | 2017-10-18 |
| CO2017005538A2 (es) | 2017-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171060A1 (es) | Receptores quimericos de antigeno anti-cldn y metodos de uso | |
| PH12017501039A1 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| EP3872094A3 (en) | Antibodies targeting b-cell maturation antigen and methods of use | |
| PH12017501521A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
| EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
| PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
| MX2021010471A (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr. | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| PH12016501894A1 (en) | Anti-ox40 antibodies and methods of use | |
| MX360707B (es) | Receptor antigénico quimérico. | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| MX386587B (es) | ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO. | |
| EP3702372A3 (en) | Anti-cd40 human antibodies | |
| PH12020550908A1 (en) | Anti-cxcr5 antibodies and compositions and uses thereof | |
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| AR098408A1 (es) | Anticuerpos específicos para fcrn | |
| MX2023006786A (es) | Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. | |
| EA201790314A1 (ru) | Новые антитела, направленные на fc-гамма-рецептор iib и fc-эпсилон-рецептор | |
| WO2018227063A8 (en) | Anti-robo2 antibodies, compositions, methods and uses thereof | |
| AR102495A1 (es) | Anticuerpos contra el dominio 3 de la inmunoglobulina y de la mucina del linfocito t (tim3) y métodos de uso | |
| MX2019002349A (es) | Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control. | |
| AR107223A1 (es) | Anticuerpos dirigidos contra upk1b y métodos para su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |